The Mumbai based leading pharmaceutical company Ipca Laboratories has received US FDA marketing approval for metoclopramide tablets DSP 5mg and 10mg. Ipca is marketing this product in alliance with Ranbaxy Pharmaceutical Ltd, a US subsidiary of Ranbaxy Laboratories.
The total annual market sales for metoclopramide tablets in US were US $27 millions. This is the sixth such product approval received under the alliance from US FDA.
Ipca will manufacture and Ranbaxy will market this formulation in the US healthcare system using Ipca's DMF approved active pharmaceutical ingredient (API) metoctopramide. Ranbaxy will commercialise this product in the US market utilizing its established marketing expertise and distribution network.
The company has its exports to over 110 countries across the globe which is contributed about 50 per cent of the company's income of Rs 1085 crore in the financial year 2007-08.